AFFF firefighting foam lawsuit MDL 2873: how the PFAS personal injury litigation actually works
The AFFF firefighting foam litigation is one of the largest active mass torts in the United States, with MDL 2873 (In re: Aqueous Film-Forming Foams Products Liability Litigation) consolidating more than 15,200 personal injury cases plus thousands of water contamination claims as of April 2026. The case theory alleges that aqueous film-forming foam, used for decades to extinguish liquid fuel fires at military bases, airports, firefighter training facilities, and industrial sites, contains per- and polyfluoroalkyl substances (PFAS) including perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) that don't degrade naturally and accumulate in the human body. Firefighters, military personnel, airport workers, and residents living near contaminated sites who developed cancer or other serious health conditions allege the manufacturers knew of the cancer risks but continued selling AFFF for decades without adequate warnings.
The litigation is centralized in the U.S. District Court for the District of South Carolina before Judge Richard M. Gergel. The MDL was created on December 7, 2018 by consolidation of approximately 75 lawsuits. As of April 2026 the docket has grown to 15,222 pending personal injury cases, with the case count increasing by approximately 1,000 cases per month through 2025 as plaintiffs' counsel screened and signed up additional clients. The water contamination side of the litigation (cases brought by public water suppliers, municipalities, and states alleging AFFF contamination of drinking water sources) has produced substantial settlements that have reshaped the broader PFAS regulatory and litigation environment.
The personal injury bellwether trials have been delayed multiple times. The first bellwether trial was scheduled for October 6, 2025 focusing on kidney cancer claims but was vacated by Case Management Order No. 35 on August 15, 2025. The court has been working through Daubert challenges and scientific evidence questions through "Science Day" proceedings, including a June 20, 2025 session focused on thyroid and liver cancer causation. The bellwether trial schedule is being reset as the science proceedings continue. When personal injury bellwethers do reach trial, the verdicts will substantially affect settlement valuation across the broader inventory of cases.
This is the science behind the PFAS-cancer theory, the procedural history of the MDL, the settlements that have already occurred on the water contamination side, the eligibility framework for filing-eligible personal injury claims, and the strategic considerations for both pending and prospective plaintiffs.
What AFFF is and why it matters
AFFF (aqueous film-forming foam) is a specialized firefighting foam developed in the 1960s by the U.S. Navy and 3M for use against liquid fuel fires that water alone cannot extinguish. The foam creates a film over the burning liquid that smothers the fire and prevents reignition. AFFF was the standard firefighting agent for military bases, civilian airports, oil refineries, chemical plants, and similar high-risk facilities for more than 50 years.
The foam's effectiveness comes from PFAS compounds, particularly PFOA and PFOS. These compounds are extraordinarily stable carbon-fluorine bonds that don't break down naturally in the environment, leading to their common name "forever chemicals." PFAS compounds:
Resist water and oil, which is why they make effective firefighting foam.
Don't degrade in the environment under normal conditions; PFAS contamination persists for decades or longer.
Bioaccumulate in human and animal tissue. Once absorbed, PFAS compounds remain in the body for years.
Have been linked through scientific research to multiple cancers and other serious health conditions.
The widespread use of AFFF created persistent environmental contamination at hundreds of military bases, airports, and industrial sites. Groundwater contamination from AFFF use has affected drinking water supplies in communities surrounding these sites. The Department of Defense identified over 600 military installations with confirmed or suspected PFAS contamination, and the Environmental Protection Agency has identified thousands of additional contamination sites nationwide.
The Department of Defense required transition away from AFFF as of October 1, 2024, replacing it with fluorine-free firefighting foam alternatives. The transition reflects acknowledgment of the long-term contamination and health risks from continued AFFF use.
The science: PFAS and cancer
The scientific evidence linking PFAS exposure to cancer and other diseases has strengthened substantially over the past decade. Key findings:
Kidney cancer. The strongest scientific evidence links PFAS exposure to renal cell carcinoma. Multiple peer-reviewed studies have established the connection, including population-level studies of firefighters and military personnel with elevated PFAS exposure.
Testicular cancer. Strong scientific evidence links PFAS exposure to testicular germ cell tumors. A 2023 study by the National Cancer Institute found statistically significant association between PFAS exposure and testicular cancer among U.S. service members.
Thyroid cancer and thyroid disease. Growing evidence links PFAS exposure to thyroid cancer, thyroid nodules, and various thyroid function abnormalities. The Court held a dedicated Science Day on June 20, 2025 focused on thyroid and liver cancer causation questions.
Liver cancer and liver disease. Evidence is developing for liver cancer and various liver function abnormalities including elevated liver enzymes and fatty liver disease.
Ulcerative colitis. Strong scientific evidence links PFAS exposure to ulcerative colitis and other inflammatory bowel diseases.
Prostate cancer. Some studies suggest association between PFAS exposure and prostate cancer, though the evidence is less definitive than for kidney and testicular cancer.
Other conditions. High cholesterol, pregnancy-induced hypertension, pre-eclampsia, reduced immune response to vaccinations, and various other conditions have shown statistical association with PFAS exposure.
The mechanism of PFAS toxicity is multi-faceted. PFAS compounds disrupt cellular processes through multiple pathways, accumulate in liver and kidney tissues, and persist in the body for years (PFOS has a half-life of approximately 5.4 years in humans). The bioaccumulation means even relatively low chronic exposure can result in significant body burden over time.
Studies have shown that firefighters have approximately triple the PFAS levels in their blood compared to the general population. Military service members at affected installations show similar elevated levels. The exposure pathways include direct skin contact with foam (recent research confirmed dermal absorption can be significant), inhalation during foam deployment, and ingestion through contaminated water.
The water contamination settlements
The water contamination side of the litigation has produced substantial settlements that have established the litigation framework:
3M Public Water Suppliers Settlement. Final approved April 1, 2024 at up to $10.3 billion (present value) over 13 years to help U.S. public water suppliers test for and remove PFAS. The settlement covers public water systems serving more than 300 million Americans and represents the largest PFAS-related corporate settlement to date. The settlement is tied to the South Carolina MDL proceedings and accelerated attention on individual personal injury claims.
DuPont/Chemours/Corteva Water Systems Settlement. Approved June 2, 2023, $1.185 billion fund to resolve a defined class of water-provider claims related to PFAS in drinking water. The settlement allocated specific amounts to defined categories of water systems with documented PFAS contamination.
State attorney general settlements. Multiple state AGs have reached separate settlements with PFAS manufacturers. Minnesota's $850 million 3M settlement (2018) and various other state-level resolutions have produced billions in additional recovery for state-level PFAS remediation.
Ongoing municipal litigation. Numerous individual municipalities continue to pursue PFAS claims separately from the global settlements. Kansas City, for example, announced its participation in 2024 with claims focused on Kansas City Aviation Department locations.
The water contamination settlements don't resolve personal injury claims. The settlements fund water system testing and PFAS removal but don't compensate individuals who developed cancer or other diseases from PFAS exposure. Personal injury claims continue separately on the MDL personal injury track.
The personal injury bellwether framework
For personal injury cases, the bellwether trial framework focuses on specific cancers and exposure scenarios. Key features:
Bellwether plaintiff pool. Limited to 25 plaintiffs initially, with cases focused on kidney cancer, testicular cancer, thyroid disease, and ulcerative colitis. The Court selected these as having the strongest scientific support for general causation.
Two contamination site focus. Air Force bases in Colorado were identified as the primary contamination sites for the initial bellwether pool. This focus ties the bellwether cases to specific documented contamination patterns rather than diffuse general PFAS exposure.
Tier system. Cases are organized into tiers based on exposure documentation and medical evidence quality. Tier 1 cases have the strongest documentation; subsequent tiers have varying levels of supporting evidence.
First trial scheduling and delays. The first bellwether trial was scheduled for October 6, 2025 focused on kidney cancer. The trial was vacated by Case Management Order No. 35 on August 15, 2025. The Court continues to vet the influx of filings and align expert/Daubert schedules before resetting personal-injury trial dates.
Science Day proceedings. The Court has held Science Day sessions to educate the court on scientific evidence linking AFFF exposure to specific diseases. Science Day on June 20, 2025 focused on thyroid and liver cancer causation. Additional Science Day proceedings are expected as the bellwether schedule develops.
The bellwether outcomes will substantially affect global settlement discussions. If plaintiffs succeed in the bellwether trials, settlement pressure increases significantly. If defendants prevail, settlement value drops or settlement timing extends.
Who qualifies to file claims
The eligibility framework for personal injury claims:
Documented AFFF exposure. The claimant had documented exposure to AFFF firefighting foam through:
- Firefighting work (municipal, military, industrial, or training)
- Military service at installations using AFFF
- Airport rescue and firefighting work
- Industrial work involving AFFF
- Living in communities with documented PFAS contamination from AFFF sites
Diagnosis of qualifying disease. The claimant developed one of the conditions with established or strong-developing scientific causation:
- Kidney cancer (renal cell carcinoma)
- Testicular cancer
- Thyroid cancer
- Thyroid disease (with growing evidence)
- Liver cancer
- Ulcerative colitis
- Pancreatic cancer (some firms accept)
- Prostate cancer (some firms accept based on exposure history)
- Other PFAS-linked conditions
Temporal proximity and exposure duration. The disease developed after sufficient exposure duration to support causation. PFAS cancers typically develop after years to decades of exposure, so claimants with brief exposure followed by quick cancer diagnosis have weaker causation cases.
Medical "nexus" opinion. A medical opinion linking the specific condition to PFAS exposure. The opinion needs to be from a qualified medical professional with relevant expertise.
Evidence preservation. Personnel records, training logs, duty rosters, base or municipal testing results, medical records, and similar contemporaneous documentation. Earlier evidence preservation is easier than reconstructing the exposure history years later.
Statute of limitations compliance. State-specific limitations periods apply, typically 2-3 years from diagnosis or 1-4 years from when the connection between condition and exposure was known or should have been known. The discovery rule provides some flexibility but has limits.
Specific occupational groups with strong typical eligibility:
Firefighters who worked with AFFF in training or fire response. Documentation through fire department records, training certificates, and similar evidence.
Military service members who worked with AFFF at military installations. Documentation through DD-214 service records, base assignment history, and similar evidence.
Airport rescue and firefighting personnel at airports using AFFF. Documentation through airport employment records.
Industrial workers at facilities using AFFF including oil refineries, chemical plants, and similar facilities.
Civilians who lived in communities with documented PFAS contamination from AFFF sources and used contaminated water supplies.
Settlement landscape and projections
While no global personal injury settlement has been reached, the framework is developing:
Settlement projections. Various firms project individual settlements ranging from $20,000 to $1 million or more per plaintiff. The wide range reflects substantial differences between cases based on cancer type, exposure duration, age at diagnosis, medical complications, and case strength.
Severe cases. Plaintiffs with kidney or testicular cancer, well-documented occupational exposure, strong medical records, and significant complications typically project toward the higher end of estimates ($500,000 - $1 million+).
Moderate cases. Plaintiffs with strong causation evidence but less severe outcomes or shorter exposure histories project in the middle of the range ($150,000 - $500,000).
Weaker cases. Plaintiffs with developing-science conditions, less documented exposure, or alternative causation issues project toward the lower end ($20,000 - $150,000).
Wrongful death cases. Estates of deceased plaintiffs typically have separate value calculations that include economic damages (lost earnings, etc.) and family member damages for loss of consortium and similar non-economic harms.
The actual settlement amounts will depend substantially on bellwether trial outcomes. Settlement values typically calibrate to bellwether verdicts within roughly 50-150% of the average verdict amount, with adjustments for individual case strength.
How AFFF compares to other mass torts
The AFFF litigation has unusual features compared to other active mass torts:
Compared to Roundup litigation where the science survived Daubert challenge: Roundup cases proceeded to trial and produced substantial verdicts. AFFF follows a similar science-dependent pattern, with the bellwether trials likely to determine the litigation's trajectory.
Compared to Zantac MDL 2924 where the federal MDL was dismissed on Daubert: Zantac illustrates the catastrophic effect of Daubert exclusions on mass tort outcomes. AFFF has avoided similar dismissal so far through the careful Science Day proceedings and limited focus on cancers with strongest causation evidence.
Compared to 3M Combat Arms with the $6 billion global settlement: 3M's overall PFAS liability (including the $10.3B water settlement and pending personal injury exposure) may ultimately exceed the Combat Arms settlement. The personal injury bellwether outcomes will determine the personal injury settlement value.
Compared to Talcum powder litigation with established product liability framework: Talc litigation produced specific verdicts that drove settlement leverage. AFFF is on a similar path with bellwether trials expected to drive resolution.
Compared to Tylenol autism MDL where the federal MDL was dismissed: Both AFFF and Tylenol involve developing scientific evidence, but AFFF has stronger established science for the targeted cancers than Tylenol autism cases had.
The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. AFFF represents one of the highest-value mass torts currently in development.
Strategic considerations
For potential plaintiffs:
Don't delay filing. The MDL has growing case volume and the Court has expressed concern about unfiled claims that may complicate global settlement discussions. Tens of thousands of viable AFFF-related injury claims remain unfiled according to plaintiffs' leadership. Filing now ensures inclusion in bellwether and settlement frameworks; waiting risks exclusion from future programs.
Engage AFFF-experienced counsel. Not all mass tort firms have substantial AFFF experience. Firms with established AFFF case books typically handle these cases more effectively than general personal injury firms. Most AFFF firms offer free consultations and work on contingency basis (typically 30-40% of recovery).
Document exposure thoroughly. Personnel records, training logs, duty rosters, base assignment history, photographs of foam use, witness statements from coworkers, medical records, and similar evidence. The case strength depends substantially on documentation quality.
Obtain qualified medical opinion. Cases require medical opinion linking the specific condition to PFAS exposure. Standard treating physicians often aren't equipped to provide the specific causation opinion needed. Specialized causation experts may be needed.
Be realistic about timeline. Personal injury bellwether trials have been delayed and the framework continues to develop. Even strong cases will likely take 2-4 years to resolve. Plaintiffs need to be prepared for extended litigation timelines.
Understand the wrongful death framework. Surviving family members of deceased AFFF plaintiffs can pursue wrongful death claims. The procedural framework is somewhat different from personal injury cases.
Statute of limitations is critical. Time-barred claims won't be revived regardless of merit. The discovery rule provides some flexibility but cases involving very old diagnoses may face limitations issues. Early consultation with counsel preserves claims that might otherwise be lost.
Consider whether to file in federal MDL or state court. Some cases may have state court options as alternatives or supplements to MDL filing. The strategic analysis depends on specific case factors.
For the broader public health context, the AFFF litigation has substantial implications beyond the individual cases. The water contamination settlements have produced significant funding for PFAS remediation. Federal regulatory action including EPA designation of PFOA and PFOS as CERCLA hazardous substances flows from the same scientific evidence that supports the litigation. The Department of Defense transition away from AFFF reflects acknowledgment of the long-term harm.
For potential plaintiffs with documented exposure and qualifying diagnoses, the framework provides meaningful paths to compensation. The work is in documenting the exposure history, obtaining qualified medical opinion linking the condition to PFAS exposure, filing within applicable limitations periods, and engaging experienced counsel who can navigate the MDL procedural framework. The bellwether trial outcomes will determine the broader settlement framework that emerges, with substantial implications for the value of individual cases. For most plaintiffs, the procedural path through MDL 2873 provides the most efficient route to recovery, with the recognition that the framework continues to develop and that the timeline for resolution depends on factors outside any individual plaintiff's control.